RESEARCH METHOD / DOSE CONTEXT
CJC-1295: the doses used in the published studies
What was administered, to which species, by which route, in the peer-reviewed record — stated as research methodology. CJC-1295 has no approved human use, so none of this is a recommendation.
What doses were used in the published studies
The doses used in CJC-1295 research are a short, specific list — and they describe study design, not a dosing guide. In the human pharmacokinetic studies, single subcutaneous doses of 30, 60, or 90 micrograms/kg were administered to healthy adults [1][3]. In the GHRH-knockout mouse growth study, 2 micrograms per dose was given at 24-, 48-, or 72-hour intervals [4]. Those are the figures with peer-reviewed provenance.
Everything circulating beyond that list lives in a different evidence state. Community and clinic "protocols" for no-DAC Modified GRF 1-29 and for CJC-1295/ipamorelin commonly cite fixed 100-300 microgram doses, but these are not derived from controlled human trials [1]. This page reports the research doses and flags the protocol claims as unverified; it does not translate either into a human course of administration.
Route, half-life, and study duration
The route across the published studies is subcutaneous injection, with intravenous administration used in the early GRF(1-29) pharmacokinetic work [10]. Oral bioavailability is negligible — CJC-1295 is a peptide and would be digested — so no oral route appears in the literature.
Duration of action is the dimension that depends entirely on variant, and it is covered in full under pharmacokinetics and half-life. In brief: the DAC variant's estimated half-life is 5.8 to 8.1 days, with IGF-1 elevated up to about 28 days after multiple doses [1]; the no-DAC Modified GRF 1-29 is short-acting, on the timescale of native GHRH(1-29) clearance [8]. Study durations followed those kinetics — the human PK studies tracked GH and IGF-1 for one to several weeks after dosing to capture the long tail [1][3].
Why the doses differ by variant
The studied doses cannot be read without the variant attached, because dosing frequency in the research tracked the half-life directly. The DAC variant's multi-day half-life (5.8 to 8.1 days) is what allowed the murine work to space doses out: 2 micrograms once every 24 hours fully normalized growth in GHRH-knockout mice, while every-48-to-72-hour dosing was progressively less effective [4][1]. That is a finding about a long-acting molecule, and it does not transfer to the short-acting no-DAC form, whose minutes-to-hours clearance implies a different administration logic entirely [8].
This is why importing a microgram figure from one variant to the other is a category error, and why this site keeps the DAC vs no-DAC (Modified GRF 1-29) distinction in front of any dose discussion. The 30/60/90 microgram/kg human figures are DAC-variant PK doses [1][3]; the fixed 100-300 microgram "protocol" numbers that circulate online are most often quoted for the no-DAC form or the ipamorelin pairing and have no controlled-trial provenance for either [1]. The honest summary is that the literature establishes what was administered in a handful of pharmacokinetic studies, and nothing more granular than that.
How research handling actually works
How much CJC-1295 should I take?
Published human PK studies used single subcutaneous doses of 30, 60, or 90 micrograms/kg [1][3]. These describe research dosing, not a human recommendation; CJC-1295 has no approved human use.
How to reconstitute CJC-1295?
In research handling, the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated; oral bioavailability is negligible, so the studied routes are subcutaneous (primary) and intravenous (early GRF(1-29) PK work) [10]. This describes laboratory handling, not human-use instructions.
Where to inject CJC-1295?
The route used across the published studies is subcutaneous injection, with intravenous used in early GRF(1-29) pharmacokinetic work [10]. This reflects research methodology; CJC-1295 has no approved human administration.